Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Cassava, SEC
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial Alzheimer’s drug,
Cassava Sciences Shares Lower Premarket on $40M Penalty to Settle Doctored Data Claims
The SEC also said Dr. Hoau-Yan Wang, a Cassava consultant, was charged with manipulating the reported clinical trial results. Without admitting or denying the violations, Wang agreed to cease and desist from future violations and to pay a monetary penalty, the SEC said.
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the Alzheimer's drug simufilam, and agreed to pay fines.
34m
on MSN
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, HP Inc., and More
Bristol Myers surges after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at ...
43m
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Shares of Cassava Sciences, Inc. SAVA fell sharply in today's pre-market trading after the SEC charged the company, two ...
15h
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
1d
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
2d
on MSN
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...
2d
We can get out of our debts by planting enough cassava – Kofi Koranteng
Kofi Koranteng, a presidential candidate for the 2024 elections for the New Vision Movement, has expressed his thoughts on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Costco
Bristol Myers
EchoStar
Southeastern Conference
Alzheimer
Feedback